Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 28.78 USD 3.9% Market Closed
Market Cap: 4.7B USD
Have any thoughts about
Alkermes Plc?
Write Note

Alkermes Plc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alkermes Plc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Alkermes Plc
NASDAQ:ALKS
Cash from Operating Activities
$356m
CAGR 3-Years
37%
CAGR 5-Years
32%
CAGR 10-Years
26%
Amarin Corporation PLC
NASDAQ:AMRN
Cash from Operating Activities
-$18.4m
CAGR 3-Years
38%
CAGR 5-Years
11%
CAGR 10-Years
15%
Prothena Corporation PLC
NASDAQ:PRTA
Cash from Operating Activities
-$153.3m
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
No Stocks Found

Alkermes Plc
Glance View

Market Cap
4.7B USD
Industry
Biotechnology

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

ALKS Intrinsic Value
28.59 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Alkermes Plc's Cash from Operating Activities?
Cash from Operating Activities
356m USD

Based on the financial report for Sep 30, 2024, Alkermes Plc's Cash from Operating Activities amounts to 356m USD.

What is Alkermes Plc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
26%

Over the last year, the Cash from Operating Activities growth was 21%. The average annual Cash from Operating Activities growth rates for Alkermes Plc have been 37% over the past three years , 32% over the past five years , and 26% over the past ten years .

Back to Top